The Annals of Haematology last month published results from the phase 2 LEGEND study. The aim of the study was to find out whether a chemo-immunotherapy (chemotherapy with antibody therapy) regimen that includes the targeted drug lenalidomide is as effective as a standard chemo-immunotherapy regimen for people with diffuse large B-cell lymphoma (DLBCL) that has relapsed (come back) or is refractory (didn’t respond) to previous treatment.
Participants in the study were treated with one of the following regimens:
- R-GEM-P (the standard treatment): rituximab combined with the chemotherapy drugs gemcitabine and cisplatin and the steroid methylprednisolone.
- R-GEM-L (the study treatment): lenalidomide combined with rituximab, gemcitabine and methylprednisolone.
The trial stopped recruiting new participants earlier than planned because preliminary results showed that neither of the treatment groups reached a very stringent, pre-defined response threshold. However, people who had already entered the study were allowed to continue.
The study authors analysed results from 34 people who took part in the study: 18 in the R-GEM-L group and 16 in the R-GEM-P group. Outcomes were similar in the two treatment groups. The authors concluded that the treatments seemed comparable in terms of efficacy and tolerability. The results suggested that R-GEM-L might be associated with fewer serious side effects than R-GEM-P, but the study was too small for this to be certain.
18 February 2020